Literature DB >> 19018978

Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma.

Tetsuya Hosaka1, Kenji Ikeda, Masahiro Kobayashi, Miharu Hirakawa, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Hiromitsu Kumada.   

Abstract

BACKGROUND: The tumour recurrence rate after resection is still high even in patients with small hepatocellular carcinoma (HCC). The advanced patterns of recurrence occasionally occur after resection. In this study, we analysed the clinical and histological characteristics of small HCC and evaluated the predictive factors of advanced tumour recurrence.
METHODS: One hundred and sixty-five patients underwent resection of small HCC measuring 3 cm or less in greatest dimension. Patterns of tumour recurrences were classified into advanced recurrence and minor recurrence based on size, number, vascular invasion and extrahepatic metastasis of recurrent tumour. We created a simple index to closely evaluate the malignant potential of small HCC, named alpha-foetoprotein-size ratio index (ASRI).
RESULTS: Overall tumour recurrence was significantly associated with tumour multiplicity (P<0.001) and ASRI (P=0.001). Tumour multiplicity, ASRI and tumour differentiation were independent and significant predictive factors of advanced recurrences. The overall survival rates were lower in the advanced recurrence group than the minor recurrence or the no recurrence group.
CONCLUSIONS: Patients with advanced recurrences have a poor prognosis, although they have undergone curative resection of small HCC. On the other hand, patients with minor recurrences have a relatively good prognosis. ASRI was a useful index to predict advanced recurrence after curative resection of small HCC. The therapeutic management to prevent advanced recurrences is needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19018978     DOI: 10.1111/j.1478-3231.2008.01901.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  9 in total

1.  Proposal of new classification for postoperative patients with hepatocellular carcinoma based on tumor growth characteristics.

Authors:  Cui-Hong Zhu; Xiao-Hui Liu; Rui Cao; Xiong-Zhi Wu
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

2.  Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma.

Authors:  Hung-Hsu Hung; Chien-Wei Su; Chiung-Ru Lai; Gar-Yang Chau; Che-Chang Chan; Yi-Hsiang Huang; Teh-Ia Huo; Pui-Ching Lee; Wei-Yu Kao; Shou-Dong Lee; Jaw-Ching Wu
Journal:  Hepatol Int       Date:  2010-09-24       Impact factor: 6.047

3.  Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma.

Authors:  Zhe Guo; Le-Qun Li; Jing-Hang Jiang; Chao Ou; Li-Xia Zeng; Bang-De Xiang
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

4.  A Novel Score Predicts HBV-Related Hepatocellular Carcinoma Recurrence After Hepatectomy: a Retrospective Multicenter Study.

Authors:  Wei Qin; Li Wang; Beiyuan Hu; Shusheng Leng; Huan Tian; Huanxian Luo; Jia Yao; Xiaolong Chen; Chao Wu; Guihua Chen; Yang Yang
Journal:  J Gastrointest Surg       Date:  2018-11-16       Impact factor: 3.452

5.  α-fetoprotein-to-total tumor volume ratio predicts post-operative tumor recurrence in hepatocellular carcinoma.

Authors:  Yun-Hsuan Lee; Chia-Yang Hsu; Yi-Hsiang Huang; Chien-Wei Su; Han-Chieh Lin; Cheng-Yuan Hsia; Teh-Ia Huo
Journal:  J Gastrointest Surg       Date:  2012-11-28       Impact factor: 3.452

6.  Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy.

Authors:  Teh I Huo; Chia Y Hsu; Yi H Huang; Chien W Su; Han C Lin; Rheun C Lee; Yi Y Chiou; Jen H Chiang; Pui C Lee; Shou D Lee
Journal:  BMC Gastroenterol       Date:  2010-12-31       Impact factor: 3.067

7.  RAM score is an effective predictor for early mortality and recurrence after hepatectomy for hepatocellular carcinoma.

Authors:  Heng-Yuan Hsu; Ming-Chin Yu; Chao-Wei Lee; Hsin-I Tsai; Chang-Mu Sung; Chun-Wei Chen; Shu-Wei Huang; Cheng-Yu Lin; Wen-Juei Jeng; Wei-Chen Lee; Miin-Fu Chen
Journal:  BMC Cancer       Date:  2017-11-09       Impact factor: 4.430

8.  Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection.

Authors:  Chao He; Wei Peng; Chuan Li; Tian-Fu Wen
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

9.  The different effects of adefovir dipivoxil and telbivudine on the prognosis of hepatitis b virus-related hepatocellular carcinoma patients after curative resection.

Authors:  Linye He; Zijing Xia; Junyi Shen; Xiaoyun Zhang; Wei Peng; Chuan Li; Tianfu Wen
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.